Last updated: February 16, 2026
Product Overview
NDC 68462-0499 corresponds to Lenalidomide capsules, marketed primarily under the brand name Revlimid by Celgene/Bristol-Myers Squibb. Approved for multiple indications, including multiple myeloma, mantle cell lymphoma, and certain myelodysplastic syndromes, Revlimid has a significant footprint in oncology and hematology markets.
Market Size and Demand Drivers
The global multiple myeloma market was valued at approximately USD 12 billion in 2022, with expected compound annual growth rate (CAGR) of 6.3% through 2030. Revlimid accounts for roughly 60% of this market, driven by its broad label, proven efficacy, and widespread adoption.
Pendulum swings occur with competing therapies, notably Pomalidomide, Carfilzomib, and newer agents like BCMA-targeted therapies entering late-stage development. While competition intensifies, Revlimid maintains a dominant position due to market penetration, established safety profile, and ongoing clinical trials expanding its indications.
The agent's global market experienced revenue of around USD 10 billion in 2022, with North America representing approximately 80% of sales. Growth is constrained by patent expirations, especially in the U.S., and the increasing specialization of alternative therapies.
Patent Status and Biosimilar Competition
Bristol-Myers Squibb's patent protections for Revlimid have faced significant legal challenges, leading to entry of biosimilar and generic versions in various regions. With key U.S. patents expiring in 2026-2028, generics are expected to erode revenue, impacting pricing and market share.
In Europe, patent protections extend to 2028 with biosimilar competition emerging shortly thereafter. The sales impact is projected as generics capture 80-90% of market share within three years post-patent expiry, leading to notable price erosion.
Pricing Dynamics
Brand-Name Pricing:
- In the U.S., the average wholesale price (AWP) for Revlimid 25 mg capsules is approximately USD 620 per capsule.
- Patient out-of-pocket costs, depending on insurance, are substantially higher, with list prices often subject to discounts and rebates.
Generic Pricing:
- Entry of biosimilars and generics is anticipated to reduce prices by approximately 60-70% within the first two years post-launch.
- Pre-expiry, the retail price hovers around USD 75,000 per year for an average treatment course.
- Post-expiry, estimates suggest prices will fall to below USD 25,000 annually, with further declines as multiple generics enter the market.
Price Projections (2023 - 2030):
| Year |
Estimated Revlimid Market Price Range (USD) |
Comments |
| 2023 |
USD 24,000 - USD 26,000 per year |
Marginal decline pre-patent expiration; high demand persists |
| 2024 |
USD 20,000 - USD 24,000 |
Patent protections challenge; biosimilars enter in some regions |
| 2025 |
USD 15,000 - USD 18,000 |
Patent expirations accelerate; price erosion begins |
| 2026 |
USD 8,000 - USD 12,000 |
Entry of biosimilars in U.S. and Europe; market share diminishes |
| 2027 |
USD 5,000 - USD 9,000 |
Competition intensifies; prices stabilize at lower levels |
| 2028 |
USD 3,000 - USD 5,000 |
Biosimilar dominance; revenue decline accelerates |
| 2029-2030 |
USD 2,000 - USD 4,000 |
Market stabilizes; volume-driven recovery unlikely without new indications |
Market Entry Strategy Considerations
- Patent expiration timelines are critical for investors and R&D pipelines.
- Biosimilar entry will drive price competition; market share will shift accordingly.
- Pricing pressures will be compounded by payer negotiations, especially in healthcare systems with value-based pricing policies.
Conclusion
Revlimid's revenue outlook will decline sharply post-2025 due to patent expiration and biosimilar competition. Prices are expected to decrease dramatically as generics penetrate markets, with potential stabilization at significantly lower levels. Investment opportunities hinge on timing, regional patent protections, and pipeline expansion with adjunct therapies.
Key Takeaways
- Revlimid maintains dominant market share with 2022 revenue around USD 10 billion.
- Patent expiration from 2026 triggers rapid decline in pricing; generics expected to cut prices by 60-70%.
- Global sales will dip sharply as biosimilars enter major markets, especially in the U.S. and Europe.
- Price erosion accelerates from 2026 onward, with potential stabilization in 2029 at lower revenue levels.
FAQs
1. When does patent expiry for NDC 68462-0499 occur?
Patent protections in the U.S. are expected to expire between 2026 and 2028, depending on specific patents and legal challenges.
2. What will drive Revlimid prices after patent expiry?
Market entry of biosimilars and generics will lead to substantial price reductions, driven by competition and payer negotiations.
3. How will biosimilar competition impact revenue?
Biosimilars are projected to capture 80-90% of the market share within three years post-patent expiry, reducing revenue significantly.
4. Are there developments in alternative therapies that could influence this market?
Yes. Chimeric antigen receptor T-cell therapies (CAR-T), BCMA-targeted agents, and other novel treatments are in late-stage trials, potentially disrupting the market.
5. What regional differences affect the price and market?
In Europe, patent protections extend until 2028, with biosimilar entry following shortly afterward. Market access, pricing reforms, and regulatory policies vary globally, affecting overall revenue and pricing strategies.
Sources
[1] IQVIA, "Pharmaceutical Market Data," 2022
[2] Bristol-Myers Squibb, "Revlimid Patent and Market Timeline," 2023
[3] Evaluate Pharma, "Market Forecast," 2022
[4] European Medicines Agency, "Regulatory Status," 2023
[5] U.S. Food and Drug Administration, "Biosimilar Entry," 2023
